{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,12]],"date-time":"2026-04-12T07:43:47Z","timestamp":1775979827875,"version":"3.50.1"},"reference-count":27,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T00:00:00Z","timestamp":1749513600000},"content-version":"vor","delay-in-days":9,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["bjui-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["BJUI Compass"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>This study aims to determine the oncological effectiveness and adverse\u2010effect profile of the Moscow strain of intravesical bacille Calmette\u2013Gu\u00e9rin (BCG) for intermediate and high\u2010risk non\u2010muscle invasive bladder cancer (NMIBC).<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and methods<\/jats:title><jats:p>We performed a retrospective search of consecutive intermediate and high\u2010risk non\u2010muscle invasive bladder cancer patients who were started on intravesical BCG at 80\u2009mg dose from January 2020 to December 2021. Data were collected for oncological outcomes and adverse effects of BCG. High\u2010grade recurrence\u2010free survival (HGRFS) was defined as any relapse of high\u2010grade (HG) urothelial cancer or carcinoma in situ (CIS). The primary outcome was to determine the HGRFS for those with originally HG disease. The RFS and HGRFS were calculated for the entire cohort, and also stratified by whether the patients had received adequate BCG or not.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>We identified 166 patients during the study period, of which 79.6% had HG disease. There were 25 recurrences (15.1%) in the entire cohort over a median follow\u2010up of 29\u2009months. The RFS for the entire cohort at 12 and 24\u2009months was 89.8% and 86.7%, respectively. For those with baseline HG disease, the 12\u2010 and 24\u2010month HG\u2010RFS was 90.9% and 87.1%. For the overall cohort, those who had received adequate BCG (<jats:italic>n<\/jats:italic>\u2009=\u2009130, 78.3%) had a 12\u2010 and 24\u2010month RFS of 96.9% and 95.4%, which was significantly higher than those who were not able to receive adequate BCG (<jats:italic>n<\/jats:italic>\u2009=\u200931, 18.6%) (12\u2010 and 24\u2010month RFS of 74.2% and 64.5%), <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001. Around 10% patients dropped out at each sequential maintenance phase, either because of BCG intolerance or because of failure to comply with the BCG instillation schedule. Severe side effects led to BCG discontinuation in 38.5% patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The Moscow strain BCG at 80\u2009mg dose has excellent oncological outcomes, especially in patients who can take adequate BCG instillations, but BCG intolerance is a problem in a significant proportion of patients.<\/jats:p><\/jats:sec>","DOI":"10.1002\/bco2.70034","type":"journal-article","created":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T05:04:07Z","timestamp":1749531847000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Real\u2010world oncological and toxicity outcomes with the Moscow strain of intravesical BCG for non\u2010muscle invasive bladder cancer\u2014Implications for global shortage"],"prefix":"10.1002","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0507-7854","authenticated-orcid":false,"given":"Amandeep","family":"Arora","sequence":"first","affiliation":[{"name":"Division of Uro\u2010Oncology, Department of Surgical Oncology Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), Tata Memorial Centre, Homi Bhabha National Institute  Mumbai India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sugam","family":"Godse","sequence":"additional","affiliation":[{"name":"Division of Uro\u2010Oncology, Department of Surgical Oncology Tata Memorial Hospital, Homi Bhabha National Institute  Mumbai India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahendra","family":"Pal","sequence":"additional","affiliation":[{"name":"Division of Uro\u2010Oncology, Department of Surgical Oncology Tata Memorial Hospital, Homi Bhabha National Institute  Mumbai India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ankit","family":"Misra","sequence":"additional","affiliation":[{"name":"Division of Uro\u2010Oncology, Department of Surgical Oncology Tata Memorial Hospital, Homi Bhabha National Institute  Mumbai India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ravi Teja","family":"Sepuri","sequence":"additional","affiliation":[{"name":"Division of Uro\u2010Oncology, Department of Surgical Oncology Tata Memorial Hospital, Homi Bhabha National Institute  Mumbai India"},{"name":"Department of Urology Kurnool Medical College  Kurnool India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naveen Thimiri","family":"Mallikarjun","sequence":"additional","affiliation":[{"name":"Division of Uro\u2010Oncology, Department of Surgical Oncology Tata Memorial Hospital, Homi Bhabha National Institute  Mumbai India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ajit","family":"Gujela","sequence":"additional","affiliation":[{"name":"Division of Uro\u2010Oncology, Department of Surgical Oncology Tata Memorial Hospital, Homi Bhabha National Institute  Mumbai India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sachin","family":"Patel","sequence":"additional","affiliation":[{"name":"Division of Uro\u2010Oncology, Department of Surgical Oncology Tata Memorial Hospital, Homi Bhabha National Institute  Mumbai India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anuj","family":"Sharma","sequence":"additional","affiliation":[{"name":"Division of Uro\u2010Oncology, Department of Surgical Oncology Homi Bhabha Cancer Hospital and Research Centre  New Chandigarh India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Santosh","family":"Menon","sequence":"additional","affiliation":[{"name":"Division of Uro\u2010Oncology, Department of Surgical Oncology Tata Memorial Hospital, Homi Bhabha National Institute  Mumbai India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ganesh","family":"Bakshi","sequence":"additional","affiliation":[{"name":"Division of Uro\u2010Oncology, Department of Surgical Oncology Tata Memorial Hospital, Homi Bhabha National Institute  Mumbai India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1722-4337","authenticated-orcid":false,"given":"Gagan","family":"Prakash","sequence":"additional","affiliation":[{"name":"Division of Uro\u2010Oncology, Department of Surgical Oncology Tata Memorial Hospital, Homi Bhabha National Institute  Mumbai India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,6,10]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.4103\/iju.iju_69_22"},{"issue":"1","key":"e_1_2_8_3_1","article-title":"Intravesical Bacillus Calmette\u2013Gu\u00e9rin versus mitomycin C for Ta and T1 bladder cancer","volume":"1","author":"Schmidt S","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2012.10.039"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2013.07.021"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.4111\/icu.20210340"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2017.01.086"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.acuro.2017.10.003"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000008300"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2014.02.061"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajur.2021.05.002"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2020.01.002"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.5489\/cuaj.8552"},{"key":"e_1_2_8_14_1","unstructured":"Verity Pharmaceuticals Inc.A Multicenter Randomized Double\u2010blind Controlled Phase III Non\u2010inferiority Study Assessing Efficacy and Safety of VERITY\u2010BCG in Management of Intermediate and High\u2010risk Non\u2010muscle Invasive Bladder Cancer (NMIBC) in BCG\u2010na\u00efve Patients. [Internet]clinicaltrialsgov;2022 Oct [cited 2024 Jan 1]. Report No.: NCT05037279.https:\/\/clinicaltrials.gov\/study\/NCT05037279"},{"key":"e_1_2_8_15_1","unstructured":"EAU guidelines. Edn. presented at the EAU Annual Congress Amsterdam.2022. ISBN 978\u201094\u201092671\u201016\u20105."},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)67707-5"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2006.04.104"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.4070"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12301-020-00099-6"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41585-021-00481-1"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1177\/1756287219833056"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00307"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-024-05218-4"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2023.09.014"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ucl.2013.01.012"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2012.09.049"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.3233\/BLC-180203"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000002740"}],"container-title":["BJUI Compass"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bco2.70034","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T17:52:36Z","timestamp":1759945956000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/10.1002\/bco2.70034"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":27,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["10.1002\/bco2.70034"],"URL":"https:\/\/doi.org\/10.1002\/bco2.70034","archive":["Portico"],"relation":{},"ISSN":["2688-4526","2688-4526"],"issn-type":[{"value":"2688-4526","type":"print"},{"value":"2688-4526","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"2025-02-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-17","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-10","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70034"}}